根据风险因素评估转移性肾细胞癌患者的真实世界结局：STAR-TOR 登记研究。
Real-world outcomes in patients with metastatic renal cell carcinoma according to risk factors: the STAR-TOR registry.
机构信息
University Medical Center Göttingen, 37075, Göttingen, Germany.
University Medical Center Hamburg-Eppendorf, 20246, Hamburg, Germany.
出版信息
Future Oncol. 2021 Jun;17(18):2325-2338. doi: 10.2217/fon-2020-1020. Epub 2021 Mar 16.
Examine outcomes in sunitinib-treated patients by International Metastatic RCC Database Consortium (IMDC) or Memorial Sloan-Kettering Cancer Center (MSKCC) risk factors. Patients enrolled in STAR-TOR registry (n = 327). End points included overall survival, progression-free survival and objective response rate. Overall survival was similar for IMDC 0 versus 1 (p = 0.238) or 2 versus ≥3 (p = 0.156), but different for MSKCC (0 vs 1, p = 0.037; 2 vs ≥3, p = 0.001). Progression-free survival was similar for IMDC 2 versus 3 (p = 0.306), but different for MSKCC (p = 0.009). Objective response rate was different for IMDC 1 (41.9%) and 2 (29.5%) and similar for MSKCC 1 (34.4%) and 2 (31.0%). Outcome data varied according to IMDC or MSKCC. MSKCC model accurately stratify patients into risk groups. NCT00700258 (ClinicalTrials.gov).
根据国际转移性肾细胞癌数据库联盟 (IMDC) 或纪念斯隆-凯特琳癌症中心 (MSKCC) 的风险因素，检查舒尼替尼治疗患者的结局。STAR-TOR 登记处招募的患者（n=327）。终点包括总生存期、无进展生存期和客观缓解率。IMDC 0 与 1（p=0.238）或 2 与≥3（p=0.156）相比，总生存期相似，但 MSKCC 不同（0 与 1，p=0.037；2 与≥3，p=0.001）。IMDC 2 与 3 相比，无进展生存期相似（p=0.306），但 MSKCC 不同（p=0.009）。IMDC 1（41.9%）和 2（29.5%）的客观缓解率不同，MSKCC 1（34.4%）和 2（31.0%）的客观缓解率相似。根据 IMDC 或 MSKCC，结局数据不同。MSKCC 模型准确地将患者分层为风险组。NCT00700258（ClinicalTrials.gov）。
Zotero 插件